Czech National Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Czech National Bank’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.9M	Buy	72,243 +3,067	+4%	+$1.36M	0.2%	90
2026 Q1	$30.9M	Buy	69,176 +2,274	+3%	+$1.06M	0.2%	92
2025 Q4	$30.3M	Buy	66,902 +1,784	+3%	+$769K	0.2%	95
2025 Q3	$25.5M	Buy	65,118 +2,348	+4%	+$981K	0.18%	106
2025 Q2	$27.9M	Buy	62,770 +3,790	+6%	+$1.75M	0.22%	90
2025 Q1	$28.6M	Buy	58,980 +3,142	+6%	+$1.46M	0.26%	80
2024 Q4	$22.5M	Buy	55,838 +3,260	+6%	+$1.51M	0.21%	90
2024 Q3	$24.5M	Buy	52,578 +3,404	+7%	+$1.64M	0.25%	77
2024 Q2	$23M	Buy	49,174 +3,832	+8%	+$1.66M	0.26%	77
2024 Q1	$19M	Buy	45,342 +203	+0.4%	+$85.8K	0.24%	84
2023 Q4	$18.4M	Buy	45,139 +29	+0.1%	+$10.7K	0.26%	80
2023 Q3	$15.7M	Buy	45,110 +14,621	+48%	+$5.11M	0.25%	85
2023 Q2	$10.7M	Buy	30,489 +194	+0.6%	+$65.4K	0.24%	87
2023 Q1	$9.55M	Buy	30,295 +249	+0.8%	+$74.7K	0.24%	94
2022 Q4	$8.68M	Buy	30,046 +242	+0.8%	+$73.8K	0.23%	103
2022 Q3	$8.63M	Buy	+29,804	New	+$8.58M	0.25%	87

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Czech National Bank's VRTX Position: Q2 2026 in Review

Czech National Bank increased its Vertex Pharmaceuticals (VRTX) stake by 4.4% in Q2 2026, buying an estimated $1.36M and bringing the position to 72,243 shares worth $35.9M. The position accounts for 0.2% of the portfolio, ranked #90.

Czech National Bank first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Czech National Bank held 72,243 shares of Vertex Pharmaceuticals worth $35.9M as of Q2 2026.
Czech National Bank bought 3,067 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.36M.
Vertex Pharmaceuticals made up 0.2% of Czech National Bank's portfolio in Q2 2026, its #90 holding.
Czech National Bank first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Czech National Bank's 13F filing for Q2 2026, filed 8 Jul 2026.